Electronic Supplementary Material: List of drugs with or without serious safety issues and classification of level of innovation:

Level of Innovation (grade) / Drugs
Withserioussafety issue
Important (A)
n=15 / miglustat, voriconazole, atazanavir, tipranavir, abacavir, tenofovir, trastuzumab, alemtuzumab, imatinib, sunitinib, natalizumab, etanercept, infliximab, verteporfin, palifermin
Moderate (B)
n=13 / rimonabant, tigecycline, entecavir, telbivudine, etravirine, bevacizumab, erlotinib, bortezomib, efalizumab, lenalidomide, ranibizumab, deferasirox, dexrazoxane
Modest (C)
n=8 / methylnaltrexone, dabigatran, romiplostim, becaplermin, panitumumab, temsirolimus, adalimumab, tocilizumab
Merely pharmacological or technological innovations
n=17 / insulin human (inhalation), rosiglitazone, pioglitazone, eptifibatide, prasugrel, dronedarone, sitaxentan, daptomycin, sirolimus, leflunomide, anakinra, valdecoxib, parecoxib, zoledronic acid, diboterminalfa, strontium ranelate, aripiprazole
Without serioussafety issue
Important (A)
n=44 / carglumic acid, agalsidase alfa, protein C agalsidasebeta, alglucosidase alfa, sodiumphenylbutyrate, nitisinone, drotrecogin alfa, protein C, caspofungin, ribavirin, amprenavir, lopinavir /ritonavir, fosamprenavir, darunavir, telaprevir, boceprevir, adefovir, emtricitabine, efavirenz, rilpivirine, emtricitabine/rilpivirine/tenovofir, enfuvirtide, raltegravir, maraviroc, pemetrexed, clofaribine, vinflunine, cabazitaxel, ipilimumab, dasatinib, bexarotene, arsenictrioxide, eribulin, abiraterone, tumor necrosis factor alfa-1a (tasonermin), daclizumab, belatacept, canakinumab, rilonacept, pirfenidone, botulinumtoxin type B, collagenaseclostridiumhistolyticum, rufinamide, omalizumab
Moderate (B)
n=50 / prucalopride, aprepitant, tocofersolan, laronidase, idursulfase, sapropterin, antithrombin alfa, ticagrelor, C1 inhibitor human, eltrombopag, conestat alfa, dofetilide, ivabradine, icatibant, tolvaptan, retapumulin, atosiban, mecasermin, aztreonam, telavancin, palivizumab, nelarabine, azacitidine, catumaxomab, ofatumumab, 5-aminolevulinic acid, temoporfin, sorafenib, nilotinib, everolimus, pazopanib, mitotane, eculizumab, fingolimod, ustekinumab, eptotermin alfa, zicotonide, levetiracetam, duloxetine, varenicline, amifampridine, fampridine, roflumilast, nitric oxide, fomivirsen, brinzolamide, bimatoprost, pegaptanib, deferiprone, ibritumomab
Modest (C)
n=26 / betaine, galsulfase, zincacetate, bivalirudin, rivaroxaban, ranolazine, cinacalcet, doripenem, temozolomide, trabectedin, cetuximab, porfimer, gefitinib, lapatinib, alitretinoin, anagrelide, mifamurtide, plerixafor, abatacept, belimumab, febuxostat, denosumab, stiripentol, memantine, sodiumoxybate, tafamidis
Merely pharmacological or technological innovations n=106 / palonosetron, fosaprepitant, insulin human (fast acting), insulin lispro, insulin aspart, insulin glulisine, insulin human (intermediate acting), insulin aspartnovomix, insulin glargine, insulin detemir, sitagliptin, vildagliptin, saxagliptin, linagliptin, nateglinide, exenatide, liraglutide, velaglucerasealfa, iloprost, tenecteplase, apixaban, fondaparinux, human fibrinogen / human thrombin, moroctocogalfa, octocogalfa, human coagulation factor IX, epoetin delta, darbepoetinalfa, epoetin theta, methoxy polyethylene glycol-epoetin beta, vernakalant, bosentan, ambrisentan, azilsartan, aliskiren, colesevelam, nicotinic acid / laropiprant, eflornithine, ethinylestradiol and norelgestromin, ulipristal, lutropinalfa, choriogonadotrophinealfa, corifollitropinalfa, bazedoxifene, lasofoxifene, oxybutynin, darifenacin, fesoterodine, apomorphine, tadalafil, vardenafil, silodosin, somatropin, pegvisomant, ganirelix, cetrorelix, teriparatide, parathyroid hormone, ertapenem, telithromycin, fidaxomicin, posaconazole, micafungin, anidulafungin, oseltamivir, human normal immunoglobulin, busulfan, cladribine, cytarabine, capecitabine, tegafur/gimeracil/oteracil, doxorubicin, degarelix, pegfilgrastim, interferon alfa-2b, interferon alfacon-1, peginterferon alfa-2a, peginterferon alfa-2b, certolizumabpegol, golimumab, characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins (ChondroCelect), capsaicin, eslicarbazepine, zonisamide, pregabalin, lacosamide, retigabine, rotigotine, rasagiline, asenapine, paliperidone, zaleplon, dexmedetomidine, agomelatine, dihydroartemisinin / piperaquine, fluticasone furoate, indacaterol, desloratadine, nepafenac, bromfenac, travoprost, emedastine, olopatadine, sugammadex, sevelamer, rasburicase

Mol et al.Post-approval safety issues with innovative drugs: a European cohort study